1087 Identification and validation of immunopeptides from novel tumor associated antigens via a multi-omics target discovery platform
Year: 2026
Type: conference-abstract
Abstract: Background Current immunotherapies show incredible promise in providing oncology patients with long-term, durable responses in traditionally difficult-to-treat cancer indications. However, many current, as well as next-generation, therapeutics have been developed against a small number of molecular targets. Combining Caris’s data repository of over 400,000 patient samples with paired whole transcriptome sequencing (WTS), whole exome sequencing (WES), and clinical outcomes we have developed a novel tumor antigen discovery pipeline to identify the next generation of immunotherapy targets.Methods The Caris patient data universe consists of 484,087 patient cases across more than 30 tumor indications. Each patient case has a complete molecular and clinical profile consisting of WTS RNA expression, WES DNA mutations, diagnostic IHC staining, clinical treatment information, and survival data. In addition, publicly available normal tissue RNA expression data from GTEx 1 and normal tissue MHC-I peptidome data from HLA-Ligand-Atlas2 were also utilized. Tumor antigens were evaluated based on RNA expression levels, screening of normal tissue MHC-I presentation, contribution to clinical outcome, correlation with immunotherapy response, MHC-I presentation predictions, and detection by mass spectrometry (MS). MS was performed in-house on a variety of tissues and cell lines, utilizing a Thermo Fisher Astral Zoom and an optimized immunopeptidomic LC/MS method, specifically designed to detect low-abundance peptides. In addition, personalized MS analysis files were created based on internal sequencing for each sample.Results High-throughput analysis of the Caris patient universe identified 104 genes with significant impact on immunotherapy response or overall survival in at least one cancer indication and cancer-restricted expression profiles matching those of known tumor associated antigens (TAAs). To date, 25 immunopeptides from 13 shared Caris TAAs have been successfully eluted from MHC-I receptors and detected via mass spectrometry, including 4 immunopeptides from primary colorectal adenocarcinoma patient samples. Efforts to further characterize these novel tumor-related immunopeptides as well as identify additional target peptides are ongoing.Conclusions Utilization of Caris’s patient data repository has identified over one hundred novel TAAs which display strong potential as immunotherapy targets. 25 MHC-I immunopeptides from 13 of these tumor antigens have been successfully detected by mass spectrometry. Four peptides belonging to these novel TAA genes have been validated by MS in primary CRC tumor tissue. Further studies to evaluate immunogenicity and T-cell reactivity are ongoing.References The Genotype Tissue Expression Project (GTEx). The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science. 2020;369:1318–1330.Marcu A, Bichmann L, Kuchenbecker L, Kowalewski DJ, Freudenmann LK, Backert L, et al. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. Journal for ImmunoTherapy of Cancer. 2021;9:e002071.
Institution: Caris Life Sciences (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W7225198409
